Shipment company

PharmaCielo Announces Shipment of Pharmaceutical Grade Cannabis Extract to Customer in Uruguay

  • This is PharmaCielo’s second shipment of pharma-grade products to a well-established Latin American pharmaceutical company with operations in Uruguay.

TORONTO and RIONEGRO, Colombia, October 12, 2022 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO) (OTCQX: PCLOF) the Canadian parent company of Colombia Leading cultivator and producer of dried cannabis flower and medicinal grade cannabis extracts, PharmaCielo Colombia Holdings SAS (“Holdings”), today announced that it has completed its second shipment of CBD isolate to the Uruguayan subsidiary of a well-established Latin American pharmaceutical company, for additional pre-market testing.

Management commentary

Bill Petron, CEO of PharmaCielocommented, “Our global business development team continues to make progress by securing PharmaCielo’s products into the hands of potential customers in new markets and turn these early relationships into business deals. We continue to expect the next twelve months to be a period of significant growth and value creation for our shareholders as the team executes the company’s growing sales pipeline. »

About PharmaCielo

PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Canada, focused on the ethical and sustainable cultivation, processing and sourcing of all pharmaceutical grade medical dried cannabis flowers and large-scale cannabis products. distributors. PharmaCielo’s The main (and wholly owned) subsidiary is PharmaCielo Colombia Holdings SAS, headquartered in its cultivation and processing center located in Rionegro, Colombia.

The board of directors and the management team of PharmaCielo are made up of a diverse group of international business leaders and specialists with relevant and varied expertise. PharmaCielo recognized the important role that Colombia the ideal location plays into building a sustainable business in the medical cannabis industry, and the company, together with its directors and officers, is executing a business plan focused on supplying the international market.

Forward-looking statements

This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as “expects”, “is expected”, “intends”, “anticipates”, “believes”, or variations of these words and expressions. or state that certain actions, events, or results “may” or “will” be taken, will occur, or will be completed or achieved.

Forward-looking statements may be affected by known and unknown risks, uncertainties and other factors, including changes in PharmaCielo’s development plans, failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of such products into other countries, TSX Venture Exchange approval, inability to export or distribute commercial products through sales channels as intended due to economic or operational circumstances, risks associated with operating in Colombiafluctuations in the market price of the Company’s products, risks associated with global economic instability related to COVID-19 or other developments, risks associated with the retention of key Company personnel, currency risk , competition in PharmaCielo’s market risks and other risks discussed or referred to under “Risk Factors” in PharmaCielo’s Annual Information Form for the year ended December 31, 2019, available at Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

THE SOURCE PharmaCielo Ltd.

© Canada Newswire, source Canada Newswire English